Dr Reddy’s enters into partnership with Hetero

24 Mar 2015 Evaluate

Dr Reddy’s Laboratories (DRL) has entered into an agreement with Hetero, under which DRL has been licensed to distribute and market Sofosbuvir 400 mg tablets, indicated in the treatment of Chronic Hepatitis C, under the brand name Resof, in India.

With the diagnosis rates for Hepatitis C in India being abysmally low, DRL will make a significant difference in the diagnosis and treatment of this disease.

Resof is a breakthrough medicine and will simplify the traditional and complicated treatment options available nowadays, allowing patients suffering from Chronic Hepatitis C access to a far more affordable and effective treatment regimen, as compared to existing ones.

Dr Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1204.50 -19.80 (-1.62%)
29-Jan-2026 12:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1599.05
Dr. Reddys Lab 1204.50
Cipla 1321.50
Zydus Lifesciences 889.75
Lupin 2121.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×